Rome IV Diagnostic Criteria for Irritable Bowel Syndrome (IBS)

Introduction

Irritable bowel syndrome (IBS) is the most prevalent functional gastrointestinal disorder worldwide and one of the most common reasons for referral to gastroenterology. It is characterized by recurrent abdominal pain associated with altered bowel habits in the absence of detectable structural or biochemical abnormalities that explain the symptoms. Despite its high prevalence, IBS remains a source of diagnostic uncertainty for many clinicians, frustration for patients, and debate among researchers regarding its underlying mechanisms.

The Rome IV classification system, published in 2016, provides the current international consensus framework for diagnosing IBS and other disorders of gut-brain interaction (DGBI), the term that replaced "functional gastrointestinal disorders" in Rome IV nomenclature. The criteria are intended to standardize diagnosis for both clinical practice and research, enabling consistent communication among providers and reproducible patient selection for clinical trials. Rome IV refined several elements from its predecessor, Rome III, making the diagnostic threshold more specific while broadening certain symptom descriptors to better reflect the clinical reality of the condition.

Historical Evolution of IBS Diagnostic Criteria

The effort to create standardized diagnostic criteria for IBS began long before the Rome Foundation. Understanding this historical arc is important for appreciating why the current criteria exist in their present form and how clinical thinking about IBS has evolved.

Manning Criteria (1978)

The Manning criteria were among the first attempts to define IBS based on positive symptom identification rather than exhaustive exclusion of organic disease. Manning and colleagues identified six symptoms that were more common in IBS than in organic gastrointestinal disease: pain relief with defecation, looser stools at onset of pain, more frequent bowel movements at onset of pain, visible abdominal distension, passage of mucus, and a sensation of incomplete evacuation. While groundbreaking, these criteria had limited sensitivity and specificity, and they did not include a temporal requirement.

Rome I and Rome II (1989-1999)

The Rome process began in 1989 with a working team that convened during the International Congress of Gastroenterology in Rome. Rome I (1992) and Rome II (1999) progressively formalized the criteria, introducing the concept of symptom duration thresholds and the requirement for abdominal pain or discomfort associated with defecation and stool changes. Rome II introduced the 12-week (not necessarily consecutive) symptom duration within 12 months.

Rome III (2006)

Rome III required recurrent abdominal pain or discomfort at least 3 days per month in the last 3 months, with symptom onset at least 6 months before diagnosis. It required at least 2 of 3 associated features: improvement with defecation, onset associated with a change in stool frequency, and onset associated with a change in stool form. Rome III introduced the Bristol Stool Form Scale as the basis for subtype classification.

Rome IV (2016)

Rome IV made several clinically meaningful changes. It eliminated the word "discomfort" from the core criterion, recognizing that this term is ambiguous and inconsistently interpreted across languages and cultures. It raised the pain frequency threshold from 3 days per month to at least 1 day per week on average, which increases specificity. It broadened the defecation-related feature from "improvement with defecation" to "related to defecation," acknowledging that some patients experience worsening of pain with bowel movements. The temporal requirement (criteria fulfilled for the last 3 months with onset at least 6 months before diagnosis) was retained.

Epidemiology

IBS is a global condition with substantial variation in reported prevalence depending on the diagnostic criteria applied, the population studied, and the methodology used.

Global Prevalence

Using Rome III criteria, worldwide prevalence estimates range from approximately 9% to 23%. With the more restrictive Rome IV criteria, prevalence estimates are generally lower, in the range of 3% to 5% in most population-based studies. The Rome Foundation Global Epidemiology Study, published in 2021, reported an overall Rome IV IBS prevalence of approximately 4.1% across 33 countries using internet-based surveys. This reduction from Rome III figures reflects the higher pain frequency threshold and the removal of "discomfort" as a qualifying symptom.

Sex and Age Distribution

IBS is more commonly diagnosed in women than in men across most populations, with a female-to-male ratio of approximately 1.5:1 to 2:1 in Western countries. This sex difference is less pronounced in Asian populations and in studies from some Middle Eastern countries. The condition most commonly presents in young to middle-aged adults, with peak prevalence between the ages of 20 and 40. However, IBS can occur at any age, including in adolescents and older adults, though new-onset symptoms after age 50 warrant more careful exclusion of organic disease.

Economic and Social Burden

The economic impact of IBS is considerable. Direct healthcare costs include physician visits, diagnostic testing, medications, and specialist referrals. Indirect costs encompass lost work productivity, absenteeism, and presenteeism (reduced productivity while at work). In the United States alone, IBS is estimated to account for over 3.5 million physician visits per year and billions of dollars in direct and indirect costs. Quality of life in IBS patients is often significantly impaired, comparable to or worse than that seen in conditions such as diabetes, chronic kidney disease, and gastroesophageal reflux disease.

Pathophysiology

IBS is now understood to be a disorder of gut-brain interaction, a term that reflects the complex bidirectional communication between the central nervous system and the enteric nervous system. No single mechanism explains all cases, and the pathophysiology is best understood as a multifactorial interplay of several processes.

Altered Gut Motility

Abnormalities in gastrointestinal motility have been documented in IBS patients, though they are neither universal nor specific. Patients with IBS-C tend to have slower colonic transit, while those with IBS-D often have accelerated transit. However, transit time alone does not fully explain symptom severity, and many patients with IBS have normal transit measurements. High-amplitude propagating contractions and exaggerated gastro-colonic reflexes have been demonstrated in some IBS-D patients, contributing to urgency and postprandial symptoms.

Visceral Hypersensitivity

Enhanced perception of visceral stimuli is one of the most consistently identified abnormalities in IBS. Balloon distension studies of the rectum and colon have shown that IBS patients report pain and discomfort at lower distension volumes and pressures than healthy controls. This visceral hypersensitivity involves both peripheral sensitization of afferent nerve fibers in the gut wall and central sensitization in the spinal cord and brain, leading to amplified pain processing. Not all IBS patients demonstrate visceral hypersensitivity on formal testing, suggesting it is one contributing factor among several.

Gut-Brain Axis Dysregulation

The gut-brain axis encompasses neural, hormonal, and immunologic communication pathways between the gastrointestinal tract and the central nervous system. In IBS, functional neuroimaging studies have shown altered activation patterns in brain regions involved in pain processing, including the anterior cingulate cortex, insula, prefrontal cortex, and amygdala. Dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis, which mediates the stress response, has also been documented. The high comorbidity of IBS with anxiety, depression, and somatoform disorders supports the role of central nervous system factors in symptom generation and perpetuation.

Intestinal Microbiome Alterations

The gut microbiome in IBS patients frequently differs from that of healthy individuals, though no single microbial signature has been identified. Common findings include reduced microbial diversity, altered ratios of Firmicutes to Bacteroidetes, and changes in specific genera such as increased Veillonella and decreased Lactobacillus and Bifidobacterium species. Small intestinal bacterial overgrowth (SIBO) has been implicated in a subset of IBS patients, particularly those with bloating and diarrhea, though the prevalence of SIBO in IBS varies widely across studies depending on the diagnostic method used.

Post-Infectious IBS

Approximately 10% to 15% of patients develop IBS following an episode of acute infectious gastroenteritis, a phenomenon termed post-infectious IBS (PI-IBS). Risk factors for PI-IBS include the severity and duration of the initial infection, female sex, younger age, psychological comorbidity at the time of infection, and the use of antibiotics during the acute episode. PI-IBS is more commonly of the IBS-D subtype and is thought to involve persistent low-grade mucosal inflammation, altered intestinal permeability, changes in enteroendocrine cells, and microbiome disruption.

Mucosal Immune Activation

Although IBS is not classified as an inflammatory disease, subtle immune activation has been identified in colonic and ileal biopsies of some patients. Increased numbers of mast cells in proximity to enteric nerves, elevated levels of mucosal cytokines, and increased intestinal permeability have been reported, particularly in PI-IBS and IBS-D. These findings suggest that low-grade immune activation may contribute to visceral hypersensitivity and altered motility in a subset of patients.

Serotonin and Neurohumoral Signaling

Serotonin (5-hydroxytryptamine, 5-HT) is a critical signaling molecule in the gut, with over 90% of the body's serotonin produced by enterochromaffin cells in the gastrointestinal mucosa. Serotonin modulates motility, secretion, and visceral sensation through multiple receptor subtypes. Abnormalities in serotonin metabolism and receptor expression have been documented in IBS, and several IBS-targeted pharmacotherapies (alosetron, ondansetron, tegaserod) act on serotonin receptor pathways.

Genetic and Epigenetic Factors

Twin studies suggest a modest heritable component to IBS, with concordance rates higher in monozygotic than dizygotic twins. However, shared environmental factors (especially early-life experiences) also contribute significantly. Candidate gene studies have identified associations with genes involved in serotonin transport (SLC6A4), inflammatory cytokines (TNF, IL-6, IL-10), and bile acid metabolism, but no single gene variant has been shown to be necessary or sufficient for IBS development.

Psychosocial Factors

Psychological distress, adverse childhood experiences, chronic life stress, and maladaptive coping strategies are strongly associated with IBS prevalence, symptom severity, and healthcare-seeking behavior. These factors influence the gut-brain axis through autonomic nervous system dysregulation, HPA axis activation, and central pain modulation. The relationship is bidirectional: gut symptoms exacerbate psychological distress, and psychological distress amplifies gut symptoms.

Rome IV Diagnostic Criteria: Detailed Breakdown

The Rome IV criteria for IBS require all of the following conditions to be satisfied. The diagnosis is made on clinical grounds after appropriate evaluation to exclude organic disease; the criteria themselves do not specify a mandatory laboratory or imaging workup.

Core Criterion: Recurrent Abdominal Pain

The patient must have recurrent abdominal pain, on average, at least 1 day per week in the last 3 months. This is the central requirement and represents a meaningful increase in specificity from Rome III, which required only 3 days per month. The term "recurrent" implies a pattern of symptoms rather than a single episode or a constant, unchanging pain. The word "discomfort," which appeared in Rome III as an alternative to "pain," was deliberately removed in Rome IV because of its inconsistent interpretation across languages and cultures. Patients who experience only bloating, distension, or irregular bowel habits without qualifying abdominal pain do not meet Rome IV IBS criteria, though they may qualify for other Rome IV diagnoses such as functional bloating or functional diarrhea.

Temporal Criterion: Duration and Onset

The diagnostic criteria must be fulfilled for the last 3 months, and symptom onset must have occurred at least 6 months prior to the time of diagnosis. This dual temporal requirement ensures chronicity and excludes acute or subacute presentations that may represent self-limited infections, medication effects, or transient functional disturbances. The 6-month onset requirement is particularly important in post-infectious scenarios, where symptoms may initially mimic IBS but resolve within weeks to months.

Associated Features: Two of Three Required

The abdominal pain must be associated with at least 2 of the following 3 features:

1. Related to Defecation

This feature asks whether the abdominal pain has a temporal or causal relationship with bowel movements. In Rome III, this criterion was narrower: "improvement with defecation." Rome IV broadened the wording to "related to defecation" to capture patients whose pain worsens with defecation or whose pain changes in character (not necessarily improves) around bowel movements. This change reflects clinical evidence that a significant proportion of IBS patients, particularly those with IBS-C, experience worsening pain with defecation attempts due to straining, incomplete evacuation, or anorectal dysfunction.

2. Associated With a Change in Frequency of Stool

This feature evaluates whether the onset or exacerbation of pain coincides with a change in how often the patient has bowel movements. The change may be an increase (more frequent stools, as in IBS-D) or a decrease (less frequent stools, as in IBS-C). The comparison is to the patient's own baseline pattern, not to a population norm. A patient who normally has one bowel movement daily and develops pain coinciding with three bowel movements daily, or conversely with one movement every three days, would satisfy this criterion.

3. Associated With a Change in Form (Appearance) of Stool

This feature asks whether pain is associated with a change in stool consistency or appearance. Stool form is assessed using the Bristol Stool Form Scale (BSS), which classifies stools into seven types ranging from hard, separate lumps (Type 1) to entirely liquid (Type 7). A shift from the patient's baseline stool form toward either extreme (harder or looser) during symptomatic periods satisfies this criterion.

The Bristol Stool Form Scale and IBS Subtyping

The Bristol Stool Form Scale (BSS) is integral to Rome IV IBS subtype classification. Developed by Lewis and Heaton in 1997, the BSS was originally designed as a surrogate marker for colonic transit time. It has since become the standard tool for characterizing stool consistency in clinical practice and research.

Scale Description

Type	Description	Clinical Correlation
Type 1	Separate hard lumps, like nuts	Slow transit; hard/lumpy category
Type 2	Sausage-shaped but lumpy	Slow transit; hard/lumpy category
Type 3	Sausage-shaped with cracks on surface	Normal transit
Type 4	Smooth and soft, like a sausage or snake	Normal transit
Type 5	Soft blobs with clear-cut edges	Normal transit
Type 6	Fluffy pieces with ragged edges, mushy	Fast transit; loose/watery category
Type 7	Watery, no solid pieces, entirely liquid	Fast transit; loose/watery category

Subtype Definitions

Rome IV classifies IBS into four subtypes based on the predominant stool pattern, using a 25% threshold applied to abnormal bowel movements. Subtype classification should be based on days when stool form is abnormal, and ideally assessed when the patient is not taking medications that alter stool consistency.

Subtype	Full Name	Definition
IBS-C	Constipation-predominant IBS	Hard or lumpy stools (BSS 1-2) in 25% or more of bowel movements, and loose or watery stools (BSS 6-7) in fewer than 25%
IBS-D	Diarrhea-predominant IBS	Loose or watery stools (BSS 6-7) in 25% or more of bowel movements, and hard or lumpy stools (BSS 1-2) in fewer than 25%
IBS-M	Mixed IBS	Hard or lumpy stools (BSS 1-2) in 25% or more AND loose or watery stools (BSS 6-7) in 25% or more of bowel movements
IBS-U	Unsubtyped IBS	Insufficient abnormality of stool consistency to meet criteria for IBS-C, IBS-D, or IBS-M

Subtype Instability

An important clinical consideration is that IBS subtypes are not fixed. Longitudinal studies demonstrate that a substantial proportion of patients (ranging from 25% to 75% depending on the study and follow-up period) change subtypes over time. A patient initially classified as IBS-C may later present with IBS-D or IBS-M. This fluidity has implications for treatment selection, trial enrollment, and long-term management planning. Patients should be subtyped based on their current predominant stool pattern and reassessed periodically.

Clinical Assessment and Diagnostic Approach

The Rome IV criteria support a positive diagnostic strategy for IBS, in which the diagnosis is made based on the presence of characteristic symptoms rather than solely through exhaustive exclusion of all possible organic diseases. This approach reduces unnecessary testing, shortens the diagnostic journey, and allows earlier initiation of treatment.

Comprehensive History

A detailed symptom history is the cornerstone of IBS diagnosis. Key elements include:

• Pain characterization: Location (often lower abdominal, but variable), quality (cramping, aching, sharp), frequency, duration of episodes, and temporal patterns (relation to meals, stress, menstrual cycle)
• Bowel habit assessment: Frequency, consistency (using Bristol Stool Form Scale), urgency, straining, sensation of incomplete evacuation, and passage of mucus
• Temporal profile: Total duration of symptoms, age at onset, pattern of symptom fluctuation, and any identifiable precipitating events (infection, surgery, psychosocial stressor)
• Dietary factors: Relationship of symptoms to specific foods, meal timing, fiber intake, lactose and fructose consumption, and use of artificial sweeteners
• Medication review: Current and recent medications that may affect bowel function (opioids, anticholinergics, NSAIDs, metformin, antibiotics, magnesium-containing antacids)
• Psychological assessment: Screening for anxiety, depression, somatization, history of trauma or abuse, and current psychosocial stressors
• Impact on daily life: Work attendance, social activities, diet restrictions, and overall quality of life

Physical Examination

The physical examination in IBS is typically unremarkable, but it serves to identify findings that would suggest organic disease. Key components include:

• General assessment of nutritional status and signs of systemic illness
• Abdominal examination for masses, organomegaly, tenderness patterns, and signs of obstruction
• Digital rectal examination, which is appropriate when constipation, rectal bleeding, or anorectal dysfunction is reported
• Evaluation for extraintestinal findings that may suggest inflammatory bowel disease (oral ulcers, joint swelling, skin lesions) or malabsorption (pallor, dermatitis herpetiformis)

Limited Laboratory Evaluation

Rome IV endorses a minimal, targeted diagnostic workup rather than a broad battery of tests. Recommended baseline investigations in most settings include:

• Complete blood count (CBC): To screen for anemia and elevated white cell count
• C-reactive protein (CRP) or fecal calprotectin: To help distinguish IBS from inflammatory bowel disease; a normal fecal calprotectin has a high negative predictive value for IBD
• Celiac disease serology (tissue transglutaminase IgA with total IgA): Recommended in all patients with IBS-D or IBS-M, and reasonable in IBS-C given the variable presentation of celiac disease

Additional testing should be guided by the clinical presentation. Thyroid function tests, stool studies for infection (particularly in endemic areas or post-travel), bile acid malabsorption testing, and hydrogen breath testing for lactose or fructose intolerance may be appropriate in selected patients. Colonoscopy is not routinely required for younger patients who meet Rome IV criteria without alarm features, but is indicated when alarm features are present or when age-appropriate colorectal cancer screening is due.

Alarm Features and Red Flags

Before applying the IBS label, clinicians must evaluate for alarm features that suggest organic pathology and warrant further investigation. The presence of any of the following should prompt additional workup beyond the minimal IBS evaluation:

• Unintentional weight loss: Significant, unexplained weight loss is atypical for IBS and suggests malabsorption, malignancy, or systemic disease.
• Rectal bleeding or melena: Although hemorrhoidal bleeding is common and benign, any report of blood in the stool requires evaluation to exclude inflammatory bowel disease, colorectal neoplasia, or vascular malformations.
• Iron deficiency anemia: Unexplained anemia raises concern for occult gastrointestinal blood loss or malabsorption (e.g., celiac disease).
• Nocturnal symptoms: IBS symptoms that consistently wake a patient from sleep are unusual and suggest organic pathology such as IBD or microscopic colitis.
• New onset of symptoms after age 50: Late-onset IBS-like symptoms carry a higher risk of organic disease, including colorectal malignancy, and warrant more thorough investigation.
• Family history of colorectal cancer, inflammatory bowel disease, or celiac disease: A strong family history lowers the threshold for endoscopic and serologic evaluation.
• Progressive symptom worsening: IBS characteristically waxes and wanes. Symptoms that are steadily progressive without remission periods should raise concern for an evolving organic process.
• Fever: Recurrent or persistent fever accompanying gastrointestinal symptoms is not consistent with IBS.
• Palpable abdominal mass or lymphadenopathy: These findings on physical examination require prompt investigation.

Differential Diagnosis

IBS shares symptoms with numerous organic and functional conditions. A systematic differential diagnosis ensures that treatable conditions are not missed.

Inflammatory Bowel Disease (IBD)

Crohn's disease and ulcerative colitis can present with abdominal pain, diarrhea, and altered bowel habits. Key distinguishing features include rectal bleeding, nocturnal diarrhea, weight loss, elevated inflammatory markers (CRP, ESR, fecal calprotectin), and extraintestinal manifestations. Fecal calprotectin is particularly valuable as a non-invasive screening tool; levels below 50 micrograms per gram have a high negative predictive value for IBD in young adults.

Celiac Disease

Celiac disease affects approximately 1% of the general population and is more prevalent among IBS patients than in the general population. It can present with diarrhea, bloating, abdominal pain, and constipation. Serologic screening (tissue transglutaminase IgA) should be performed in all patients presenting with IBS-D or IBS-M symptoms. A positive serology should be followed by duodenal biopsies for confirmation.

Microscopic Colitis

Microscopic colitis (collagenous colitis and lymphocytic colitis) presents with chronic, watery, non-bloody diarrhea and can be easily mistaken for IBS-D. The colonic mucosa appears grossly normal on colonoscopy, and diagnosis requires histologic examination of random colonic biopsies. It is most common in middle-aged and older women and is associated with autoimmune conditions and certain medications (NSAIDs, proton pump inhibitors, SSRIs).

Bile Acid Malabsorption

Bile acid malabsorption (BAM) is an underdiagnosed cause of chronic diarrhea that mimics IBS-D. It results from excess bile acids entering the colon, where they stimulate secretion and motility. Diagnosis can be made through SeHCAT testing (where available), serum 7-alpha-hydroxy-4-cholesten-3-one (C4) levels, or an empiric trial of bile acid sequestrants (cholestyramine, colesevelam). Studies suggest that BAM may account for symptoms in up to 25% to 30% of patients previously labeled as IBS-D.

Small Intestinal Bacterial Overgrowth (SIBO)

SIBO presents with bloating, flatulence, abdominal pain, and diarrhea. Diagnosis is typically made by hydrogen or methane breath testing after a glucose or lactulose challenge, though test accuracy is debated. The overlap between SIBO symptoms and IBS is substantial, and some researchers have proposed that SIBO may be a contributing factor in a subset of IBS patients rather than a completely separate entity.

Colorectal Cancer

While IBS itself does not increase colorectal cancer risk, new-onset IBS-like symptoms in patients over 50, or in younger patients with a strong family history or alarm features, require colonoscopy to exclude malignancy. Age-appropriate screening guidelines should be followed regardless of the IBS diagnosis.

Endometriosis

In women of reproductive age, endometriosis can cause cyclical abdominal and pelvic pain, bloating, and altered bowel habits that closely mimic IBS. Symptoms often correlate with the menstrual cycle. A high index of suspicion, pelvic examination, and gynecologic referral are appropriate when the clinical history suggests endometriosis.

Lactose and Fructose Intolerance

Carbohydrate malabsorption is common and can cause bloating, flatulence, abdominal pain, and diarrhea that overlap significantly with IBS. Hydrogen breath testing can confirm lactose or fructose malabsorption. Dietary elimination and rechallenge can be both diagnostic and therapeutic. Many IBS patients have concurrent carbohydrate intolerance, and addressing this component can improve symptoms even when IBS criteria remain met.

Other Functional GI Disorders

IBS frequently overlaps with other disorders of gut-brain interaction, including functional dyspepsia, functional bloating/distension, functional constipation, and functional diarrhea. Rome IV allows for multiple concurrent diagnoses when criteria for more than one disorder are met. Approximately 30% to 50% of IBS patients also meet criteria for functional dyspepsia, reflecting shared pathophysiologic mechanisms.

Management of IBS

IBS management requires a multimodal, patient-centered approach that addresses the biopsychosocial dimensions of the condition. No single intervention is effective for all patients, and treatment strategies should be tailored to the predominant symptom pattern, subtype, severity, and individual patient preferences.

Establishing the Therapeutic Relationship

The patient-physician relationship is a powerful therapeutic tool in IBS. Effective management begins with a clear, confident, positive diagnosis; a straightforward explanation of the condition and its mechanisms (using the gut-brain interaction framework); validation of the patient's symptoms; and collaborative goal-setting. Studies have shown that a strong therapeutic alliance is associated with improved symptom outcomes, greater treatment adherence, and reduced healthcare utilization.

Dietary Interventions

General Dietary Advice

First-line dietary recommendations include regular meal patterns, adequate hydration, moderation of caffeine and alcohol, reduction of gas-producing foods, and attention to fiber intake. Soluble fiber supplements (such as psyllium/ispaghula husk) have modest evidence supporting their use in IBS, particularly IBS-C, whereas insoluble fiber (wheat bran) may worsen symptoms in some patients, especially bloating.

The Low-FODMAP Diet

The low-FODMAP (Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols) diet is the most extensively studied dietary intervention for IBS. FODMAPs are short-chain carbohydrates that are poorly absorbed in the small intestine and are rapidly fermented by colonic bacteria, producing gas and drawing water into the lumen. The diet is implemented in three phases:

• Elimination phase (2 to 6 weeks): All high-FODMAP foods are restricted. Approximately 50% to 80% of IBS patients report symptomatic improvement during this phase.
• Reintroduction phase (6 to 8 weeks): Individual FODMAP groups (fructose, lactose, fructans, galacto-oligosaccharides, sorbitol, mannitol) are systematically reintroduced to identify specific triggers.
• Personalization phase (long-term): A modified diet is developed that avoids only the patient's specific triggers while maintaining the broadest possible dietary variety.

The low-FODMAP diet should ideally be supervised by a dietitian with expertise in the approach to ensure nutritional adequacy and proper reintroduction. Long-term strict FODMAP restriction is not recommended due to concerns about nutritional deficiencies and potential adverse effects on the gut microbiome.

Gluten-Free Diet

Some IBS patients report symptom improvement on a gluten-free diet despite negative celiac serology and normal duodenal biopsies. This entity, termed non-celiac gluten (or wheat) sensitivity, remains controversial. It is unclear whether the benefit is due to gluten itself, fructans in wheat (which are also restricted on a low-FODMAP diet), or other wheat components. A trial of gluten restriction may be reasonable in selected patients who have not responded to other dietary approaches, provided celiac disease has been excluded before gluten withdrawal.

Pharmacotherapy

Medications are selected based on the predominant symptom and IBS subtype. Pharmacotherapy is generally reserved for patients with moderate to severe symptoms who have not responded adequately to lifestyle and dietary modifications.

Antispasmodics

Antispasmodic agents (such as hyoscine butylbromide, dicyclomine, peppermint oil, otilonium bromide, and pinaverium) target smooth muscle contraction and are used primarily for abdominal pain and cramping. Peppermint oil in enteric-coated capsules has the best evidence base among this class, with several meta-analyses showing modest benefit over placebo for global IBS symptoms and pain. Antispasmodics are generally used on an as-needed basis rather than continuously.

Agents for IBS-C

• Linaclotide: A guanylate cyclase-C agonist that increases intestinal chloride and water secretion and has been shown to reduce abdominal pain through a separate visceral analgesic mechanism. It is FDA-approved for IBS-C.
• Plecanatide: Another guanylate cyclase-C agonist with a similar mechanism to linaclotide, also approved for IBS-C.
• Lubiprostone: A chloride channel activator that increases intestinal fluid secretion. Approved for IBS-C in women.
• Tegaserod: A 5-HT4 receptor agonist that accelerates colonic transit. It was re-approved with restrictions (women under 65 without cardiovascular risk factors) after initial withdrawal due to cardiovascular safety concerns.
• Polyethylene glycol (PEG): An osmotic laxative that improves stool frequency in IBS-C, though it has less consistent evidence for pain relief.

Agents for IBS-D

• Loperamide: An opioid receptor agonist that slows intestinal transit and reduces stool frequency. It does not improve abdominal pain and is most useful for managing diarrhea and urgency.
• Eluxadoline: A mixed mu-opioid receptor agonist and delta-opioid receptor antagonist that reduces diarrhea and abdominal pain. It is contraindicated in patients without a gallbladder and in those with a history of pancreatitis, biliary obstruction, or heavy alcohol use.
• Rifaximin: A non-absorbable antibiotic that has demonstrated benefit in IBS-D, particularly for bloating. The typical regimen is 550 mg three times daily for 14 days, with retreatment allowed for symptom recurrence.
• Alosetron: A 5-HT3 receptor antagonist that slows colonic transit and reduces visceral pain. It is approved only for women with severe IBS-D who have failed conventional therapy, due to rare but serious adverse effects including ischemic colitis and severe constipation.
• Ondansetron: A 5-HT3 receptor antagonist used off-label for IBS-D, with emerging trial evidence supporting its efficacy for stool frequency, urgency, and consistency.
• Bile acid sequestrants: Cholestyramine and colesevelam may be effective in patients with confirmed or suspected bile acid malabsorption contributing to IBS-D symptoms.

Neuromodulators (Gut-Brain Modulators)

Central neuromodulators are used for their effects on visceral pain processing, central sensitization, and psychological comorbidity:

• Tricyclic antidepressants (TCAs): Low-dose amitriptyline, nortriptyline, or desipramine (10 to 50 mg at bedtime) are among the best-studied pharmacologic interventions for IBS-related pain. They modulate pain centrally and peripherally and may slow intestinal transit, making them particularly suitable for IBS-D. The analgesic effect is independent of their antidepressant action and occurs at lower doses.
• Selective serotonin reuptake inhibitors (SSRIs): SSRIs (fluoxetine, paroxetine, citalopram) may benefit IBS patients with prominent anxiety or depression. Their effect on visceral pain is less consistent than that of TCAs, but they may accelerate colonic transit and be helpful in IBS-C patients with comorbid mood disorders.
• Serotonin-norepinephrine reuptake inhibitors (SNRIs): Duloxetine and venlafaxine are sometimes used off-label for IBS pain, particularly when there is overlapping chronic pain or fibromyalgia.

Psychological Therapies

Psychological interventions are among the most effective treatments for IBS, particularly for patients with moderate to severe symptoms, prominent psychosocial contributors, or inadequate response to pharmacotherapy.

• Cognitive behavioral therapy (CBT): The most extensively studied psychological intervention for IBS. CBT addresses maladaptive cognitions about symptoms, illness anxiety, avoidance behaviors, and stress responses. Both individual and group formats, as well as internet-delivered CBT, have demonstrated sustained benefit.
• Gut-directed hypnotherapy: Involves progressive relaxation and guided imagery focused on gut function. Multiple randomized controlled trials have shown significant and durable symptom improvement, with benefits maintained for years after treatment completion. Gut-directed hypnotherapy is recommended by multiple national guidelines.
• Mindfulness-based stress reduction (MBSR): Teaches present-moment awareness and non-judgmental acceptance of bodily sensations. Evidence for IBS benefit is growing, though less robust than for CBT or hypnotherapy.
• Psychodynamic interpersonal therapy: Addresses relationship patterns and emotional conflicts that may contribute to symptom maintenance. Limited but positive trial evidence exists.

Probiotics

Probiotics have generated substantial interest in IBS management, but the evidence remains inconsistent. Certain specific strains, notably Bifidobacterium infantis 35624 and some multi-strain preparations, have shown modest benefit for global IBS symptoms, bloating, and flatulence in randomized controlled trials. However, the field is complicated by strain-specific effects, variability in study quality, publication bias, and the absence of a clear consensus on which formulations to recommend. Probiotics are generally considered safe and may be trialed for 4 to 8 weeks, with continuation only if symptomatic benefit is observed.

Physical Activity

Regular physical activity has been associated with improved IBS symptoms in randomized controlled trials. A Swedish study demonstrated that moderate physical activity (20 to 60 minutes of moderate to vigorous exercise, 3 to 5 times per week) significantly improved constipation, bloating, and overall IBS symptom severity compared to usual care. Exercise may benefit IBS through effects on intestinal transit, stress reduction, modulation of the gut microbiome, and improvement in psychological well-being.

Special Populations and Considerations

IBS in the Elderly

IBS can occur in older adults, but new-onset IBS-like symptoms after age 50 require careful evaluation to exclude organic pathology, particularly colorectal cancer, microscopic colitis, medication-related bowel dysfunction, and ischemic colitis. The Rome IV criteria can be applied in elderly patients, but the threshold for colonoscopy and other investigations should be lower. Medication selection must account for polypharmacy, anticholinergic burden, and cardiovascular risk.

IBS in Children and Adolescents

Pediatric Rome IV criteria for IBS (Category H2a) differ from adult criteria in their wording but share the same conceptual framework. Children must have abdominal pain at least 4 days per month, associated with defecation and/or a change in stool frequency or form, for at least 2 months. The pain should not resolve solely with resolution of a stool pattern change. Management emphasizes reassurance, dietary modification, and psychological support, with pharmacotherapy reserved for refractory cases.

IBS and Pregnancy

IBS symptoms may fluctuate during pregnancy due to hormonal effects on gut motility, changes in diet and physical activity, and psychological stress. Many IBS medications are contraindicated or lack safety data in pregnancy. Management should focus on dietary modification, fiber supplementation, adequate hydration, and psychological support. Loperamide and certain antispasmodics may be used cautiously when benefits outweigh risks, but neuromodulators and newer IBS-specific agents should generally be avoided.

Overlap With Fibromyalgia and Chronic Pain Syndromes

IBS frequently coexists with fibromyalgia, chronic fatigue syndrome, chronic pelvic pain, temporomandibular joint disorder, and interstitial cystitis. This overlap is thought to reflect shared mechanisms of central sensitization and altered pain processing. Patients with overlapping conditions often have greater symptom severity and psychological comorbidity. A multidisciplinary approach that addresses both the gastrointestinal and extra-intestinal symptoms is most effective in this population.

The Role of the Rome IV Calculator in Clinical Practice

A structured tool based on the Rome IV criteria offers several advantages for clinicians evaluating patients with suspected IBS:

• Systematic assessment: Ensures that each required element (pain frequency, temporal criterion, and associated features) is explicitly evaluated, reducing the risk of incomplete assessment.
• Positive diagnosis: Supports the Rome IV philosophy of diagnosing IBS based on symptom criteria rather than solely through exclusion, encouraging confidence in the diagnosis when criteria are met and alarm features are absent.
• Subtype classification: Incorporates Bristol Stool Form Scale-based subtyping, which directly informs treatment selection.
• Documentation and communication: Provides a clear record of which criteria were met or unmet, facilitating communication between primary care and gastroenterology and supporting medicolegal documentation.
• Education: Serves as a learning tool for trainees and a reference for practicing clinicians, particularly those in primary care settings who manage the majority of IBS patients.
• Research standardization: Consistent application of Rome IV criteria enables uniform patient selection for clinical trials and epidemiologic studies.

As with all clinical tools, the calculator supplements but does not replace clinical judgment. It is designed to organize the diagnostic evaluation and highlight the key elements required for a Rome IV IBS diagnosis.

Frequently Asked Questions

Can IBS be diagnosed without a colonoscopy?

Yes. Rome IV supports a positive diagnostic approach in which IBS is diagnosed based on symptom criteria after a limited, targeted evaluation. Colonoscopy is not routinely required in younger patients (under 45 to 50, depending on guidelines) who meet Rome IV criteria without alarm features. It is indicated when alarm features are present, when age-appropriate colorectal cancer screening is due, or when there is diagnostic uncertainty despite initial workup.

What is the difference between Rome III and Rome IV for IBS?

The key changes are: Rome IV removed "discomfort" as an alternative to "pain," raised the pain frequency threshold from 3 days per month to at least 1 day per week on average, and broadened the defecation-related criterion from "improvement with defecation" to "related to defecation" (allowing for worsening). The temporal requirement (3 months of active criteria, 6-month onset history) remained the same.

Can a patient have IBS and another GI condition simultaneously?

Yes. IBS can coexist with organic gastrointestinal conditions such as celiac disease, inflammatory bowel disease in remission, bile acid malabsorption, and lactose intolerance. Rome IV allows for concurrent diagnoses. Identifying and treating a coexisting condition may improve some symptoms while the IBS component persists and requires separate management.

Do IBS subtypes change over time?

Yes. Studies consistently show that many IBS patients change subtypes over months to years. A patient classified as IBS-C at one visit may present as IBS-D or IBS-M at a later date. This instability should be communicated to patients and considered when planning long-term treatment.

Is IBS a lifelong condition?

IBS tends to be chronic and relapsing, but its severity fluctuates over time. Some patients experience prolonged periods of remission, while others have persistent symptoms. Longitudinal data suggest that approximately one-third of IBS patients improve substantially over time, one-third remain stable, and one-third experience worsening. Early and effective management, including psychological interventions, may improve long-term outcomes.

Does stress cause IBS?

Stress does not cause IBS in a simple linear sense, but it is a significant modulating factor. Stress can trigger and exacerbate IBS symptoms through effects on gut motility, visceral sensitivity, intestinal permeability, and the gut microbiome via the gut-brain axis. Conversely, chronic GI symptoms generate stress and psychological distress. This bidirectional relationship is central to the biopsychosocial model of IBS and supports the role of stress management and psychological therapies in treatment.